ARTIVION Business Summary

Artivion, Inc. (NYSE: AORT) operates a specialized medical technology business model focused on the development, manufacturing, and global distribution of advanced aortic repair solutions. The company generates revenue through transaction-based sales and service fees across two primary segments: Medical Devices and Preservation Services. The Medical Devices portfolio includes clinically differentiated products such as the E-vita Open NEO and AMDS stent grafts, On-X mechanical heart valves, and BioGlue surgical sealants, while the Preservation Services segment provides cryopreserved human cardiac and vascular tissues for transplant. Artivion competes directly with global healthcare giants including Medtronic, Edwards Lifesciences, Terumo Corporation, and LeMaitre Vascular, positioning itself as a high-growth, pure-play leader in the specialized $5.3 billion aortic disease management market. Originally founded in 1984 by Steven Anderson and Robert McNally, Artivion is currently led by Chairman, President, and CEO J. Patrick Mackin, a veteran executive with over 30 years of experience, including a tenure as President of Medtronic’s Cardiac Rhythm Disease Management division. The senior leadership team includes Lance Berry as Executive Vice President, COO, and CFO, formerly of Wright Medical, and Robert C. Thomson as Vice President of Research and Development, who spearheads the company’s innovation pipeline. Artivion is supported by a robust institutional investor base including BlackRock, Vanguard, and Morgan Stanley, with a Board of Directors featuring seasoned industry experts such as Lead Independent Director Jeffrey H. Burbank and former Medtronic Senior VP Anthony Semedo.